Subtopic Deep Dive
Cardiac Hypertrophy Signaling
Research Guide
What is Cardiac Hypertrophy Signaling?
Cardiac Hypertrophy Signaling refers to intracellular pathways including calcineurin-NFAT, MAPK, and β-adrenergic signaling that drive cardiomyocyte growth transitioning from compensatory to pathological hypertrophy in response to pressure overload.
Key pathways like calcineurin-NFAT activate transcriptional programs for hypertrophy (Molkentin et al., 1998, 2567 citations). MAPK and β-adrenergic signals contribute to maladaptive remodeling leading to fibrosis and failure (Frey and Olson, 2003, 1440 citations). Over 10 highly cited papers from 1997-2018 detail mechanisms in genetic and pressure-overload models.
Why It Matters
Understanding hypertrophy signaling enables therapies targeting calcineurin-NFAT to prevent transition to heart failure in hypertension (Molkentin et al., 1998). Nakamura and Sadoshima (2018, 1569 citations) distinguish physiological from pathological hypertrophy, guiding drugs averting fibrosis in ischemic hearts. Swynghedauw (1999, 1456 citations) links these signals to remodeling, impacting treatments for 17 million annual cardiovascular deaths globally.
Key Research Challenges
Distinguishing Adaptive vs Pathological Hypertrophy
Signaling pathways overlap between beneficial and harmful growth, complicating therapeutic targeting (Nakamura and Sadoshima, 2018). Frey and Olson (2003) note unclear molecular switches triggering failure. Models struggle to predict transition timing in pressure overload.
Pathway Crosstalk Complexity
Calcineurin-NFAT interacts with MAPK and β-adrenergic signals, yielding unpredictable outcomes (Molkentin et al., 1998). Swynghedauw (1999) highlights integrated remodeling effects. Isolating single pathways in vivo remains difficult.
Translating Models to Human Disease
Mouse genetic models overexpress hypertrophy but poorly mimic human failure progression (Frey and Olson, 2003). Olivetti et al. (1997, 1680 citations) show apoptosis in failing hearts, yet pharmacological inhibitors fail clinically. Pressure-overload replication in patients is limited.
Essential Papers
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Jeffery D. Molkentin, Jianrong Lu, Christopher L. Antos et al. · 1998 · Cell · 2.6K citations
Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
Alfred Kocher, Michael Schuster, M Szabolcs et al. · 2001 · Nature Medicine · 2.5K citations
The inflammatory response in myocardial infarction
Nikolaos G. Frangogiannis · 2002 · Cardiovascular Research · 2.0K citations
One of the major therapeutic goals of modern cardiology is to design strategies aimed at minimizing myocardial necrosis and optimizing cardiac repair following myocardial infarction. However, a sou...
Apoptosis in the Failing Human Heart
G Olivetti, Rakesh Abbi, Federico Quaini et al. · 1997 · New England Journal of Medicine · 1.7K citations
Programmed death of myocytes occurs in the decompensated human heart in spite of the enhanced expression of BCL2; this phenomenon may contribute to the progression of cardiac dysfunction.
Mechanisms of physiological and pathological cardiac hypertrophy
Michinari Nakamura, Junichi Sadoshima · 2018 · Nature Reviews Cardiology · 1.6K citations
Cardiac Fibrosis
Joshua G. Travers, Fadia Kamal, Jeffrey Robbins et al. · 2016 · Circulation Research · 1.5K citations
Myocardial fibrosis is a significant global health problem associated with nearly all forms of heart disease. Cardiac fibroblasts comprise an essential cell type in the heart that is responsible fo...
Molecular Mechanisms of Myocardial Remodeling
Bernard Swynghedauw · 1999 · Physiological Reviews · 1.5K citations
Swynghedauw, Bernard. Molecular Mechanisms of Myocardial Remodeling. Physiol. Rev. 79: 215–262, 1999. — “Remodeling” implies changes that result in rearrangement of normally existing structures. Th...
Reading Guide
Foundational Papers
Start with Molkentin et al. (1998, 2567 citations) for calcineurin-NFAT pathway discovery; Frey and Olson (2003, 1440 citations) for hypertrophy classification; Swynghedauw (1999, 1456 citations) for remodeling integration.
Recent Advances
Nakamura and Sadoshima (2018, 1569 citations) for physiological vs pathological distinctions; Travers et al. (2016, 1495 citations) linking hypertrophy to fibrosis.
Core Methods
Aortic banding for pressure overload; NFAT luciferase reporters; MAPK phosphorylation assays; genetic crosses in mice (Molkentin et al., 1998; Nakamura and Sadoshima, 2018).
How PapersFlow Helps You Research Cardiac Hypertrophy Signaling
Discover & Search
Research Agent uses searchPapers('calcineurin-NFAT cardiac hypertrophy') to retrieve Molkentin et al. (1998, 2567 citations), then citationGraph reveals 2500+ downstream papers on pathway inhibitors, while findSimilarPapers expands to MAPK crosstalk studies.
Analyze & Verify
Analysis Agent applies readPaperContent on Molkentin et al. (1998) to extract NFAT binding sites, verifyResponse with CoVe cross-checks claims against Frey and Olson (2003), and runPythonAnalysis plots signaling network statistics from 10 papers using NetworkX for pathway convergence verification with GRADE scoring.
Synthesize & Write
Synthesis Agent detects gaps in β-adrenergic to fibrosis links post-Nakamura and Sadoshima (2018), flags contradictions between mouse and human data; Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 20-paper bibliography, and latexCompile to generate review sections with exportMermaid flowcharts.
Use Cases
"Analyze dose-response of calcineurin inhibitors in hypertrophy models from 10 papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas curve fitting on extracted data) → matplotlib dose-response plots and IC50 stats.
"Draft LaTeX figure of calcineurin-NFAT vs MAPK pathways with citations"
Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (pathway schematic) → latexSyncCitations (Molkentin 1998, Frey 2003) → latexCompile → PDF output.
"Find GitHub code for cardiac hypertrophy simulation models"
Research Agent → paperExtractUrls (Swynghedauw 1999) → paperFindGithubRepo → githubRepoInspect → runnable Python model for pressure-overload simulations.
Automated Workflows
Deep Research workflow scans 50+ papers on hypertrophy signaling via searchPapers → citationGraph → structured report ranking pathways by evidence (e.g., calcineurin dominance per Molkentin). DeepScan's 7-step chain verifies Frey and Olson (2003) claims with CoVe checkpoints and runPythonAnalysis on apoptosis data. Theorizer generates hypotheses on MAPK-β-adrenergic inhibitors from Nakamura and Sadoshima (2018) contradictions.
Frequently Asked Questions
What defines Cardiac Hypertrophy Signaling?
It encompasses calcineurin-NFAT, MAPK, and β-adrenergic pathways driving cardiomyocyte enlargement from pressure overload (Molkentin et al., 1998; Frey and Olson, 2003).
What are core methods in this subtopic?
Genetic knockout models (calcineurin-NFAT), pressure-overload via aortic banding, and pharmacological inhibitors assess signaling in mice (Molkentin et al., 1998; Nakamura and Sadoshima, 2018).
What are key papers?
Molkentin et al. (1998, Cell, 2567 citations) on calcineurin pathway; Frey and Olson (2003, 1440 citations) on hypertrophy types; Nakamura and Sadoshima (2018, 1569 citations) on mechanisms.
What open problems exist?
Unclear switches from adaptive to pathological hypertrophy; poor human translation of mouse models; unresolved pathway crosstalk (Frey and Olson, 2003; Swynghedauw, 1999).
Research Cardiac Fibrosis and Remodeling with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiac Hypertrophy Signaling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cardiac Fibrosis and Remodeling Research Guide